Immunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge

<div>Treatment group survival analysis of SOT patients. CTLA-4: patients using anti-CTLA-4; CTLA-4+: patients who received sequential or concurrent anti-PD-1 and anti-CTLA-4 therapy; PD-1: patients using anti-PD-1/PD-L1.</div>

Journal of Immunology Research

fig5

Figure 5

Figure 5: Immunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge 

Figure 5 | Immunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge 